These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

937 related items for PubMed ID: 22748821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ.
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [Abstract] [Full Text] [Related]

  • 4. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G.
    Lancet; 2013 Sep 14; 382(9896):941-50. PubMed ID: 23850055
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
    Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.
    Lancet; 2013 Oct 26; 382(9902):1413-23. PubMed ID: 23948125
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ.
    Diabetes Obes Metab; 2011 Feb 26; 13(2):160-8. PubMed ID: 21199268
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.
    Cardiovasc Diabetol; 2017 Jan 21; 16(1):13. PubMed ID: 28109295
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z, Yang JK, Tong N, Yan S, Zhang X, Gong Y, Woerle HJ.
    Curr Med Res Opin; 2013 Aug 21; 29(8):921-9. PubMed ID: 23672632
    [Abstract] [Full Text] [Related]

  • 14. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigators.
    Lancet Diabetes Endocrinol; 2014 Sep 21; 2(9):691-700. PubMed ID: 24948511
    [Abstract] [Full Text] [Related]

  • 15. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.
    Diabetes Obes Metab; 2009 Feb 21; 11(2):157-66. PubMed ID: 19125777
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
    Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, Festa A, Kiljański J, Sapin H, Trautmann M, Schernthaner G.
    Lancet; 2012 Jun 16; 379(9833):2270-8. PubMed ID: 22683137
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.
    J Diabetes Complications; 2013 Jun 16; 27(3):274-9. PubMed ID: 23403068
    [Abstract] [Full Text] [Related]

  • 19. Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.
    Ren Q, Li L, Su X, Hu X, Qin G, Han J, Liu Y, Wang J, Ji L.
    Diabetes Obes Metab; 2024 Nov 16; 26(11):5013-5024. PubMed ID: 39308336
    [Abstract] [Full Text] [Related]

  • 20. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
    Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Lewis-D'Agostino D, Woerle HJ.
    Diabet Med; 2014 Dec 16; 31(12):1505-14. PubMed ID: 24824197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.